title: Sirolimus-eluting coronary stents: a review.
abstract: The sirolimus-eluting coronary stent received CE Mark approval in Europe in April 2002. In the US, FDA approval followed in April 2003. Since the preliminary results from the First-in-Man feasibility study were presented, several randomized, controlled trials have documented the profound antiproliferative effects of sirolimus, a macrolide antibiotic and potent cytostatic inhibitor of smooth muscle cell proliferation. Subsequently, the body of clinical evidence was increased by the second wave of evidence from trials in more complex lesions (such as in-stent restenosis, small vessels, chronic total occlusions) and "high-risk" patients such as those with diabetes. More recently we have had the opportunity to compare the two commercially available drug-eluting stents following the presentation of data from six head-to-head trials. As a result of numerous single and multi-center, national and international studies in which the safety and efficacy of sirolimus-eluting coronary stents have been subjected to close scrutiny, the global interventional cardiology community now has a wealth of evidence in support of the use of this technology resulting in dramatically improved patient outcomes after percutaneous intervention.
authors.affiliation: Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil. aabizaid@uol.com.br
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
mesh_terms: D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D012307:Risk Factors; D020123:Sirolimus / Q000494:pharmacology*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus